enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. SGLT2 inhibitor - Wikipedia

   en.wikipedia.org/wiki/SGLT2_inhibitor

   Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors ...

3. Empagliflozin - Wikipedia

   en.wikipedia.org/wiki/Empagliflozin

   Empagliflozin lowers risk of hospitalization and death in people with reduced heart function, when added to standard heart failure treatment with or without type 2 diabetes. [ 29 ] [ 30 ] [ 31 ] It is indicated in adults with type 2 diabetes and established cardiovascular disease to reduce the risk of cardiovascular death; and as an adjunct to ...

4. Cardiotonic agent - Wikipedia

   en.wikipedia.org/wiki/Cardiotonic_agent

   Digoxin helps alleviate symptoms and reduce hospitalizations related to heart failure, but it does not offer any mortality-reducing benefits. [86] Digoxin may be considered in patients who remain symptomatic despite receiving treatment with a first-line combination of an ACE inhibitor (or ARNI ), a beta-blocker , and a mineralocorticoid ...

5. A Common Drug Could Lower Your Dementia Risk By 35 ... - AOL

   www.aol.com/common-drug-could-lower-dementia...

   People who took SGLT-2 inhibitors for longer periods of time seemed to have the best results. “SGLT-2 inhibitors might prevent dementia, providing greater benefits with longer treatment,” the ...

6. Management of heart failure - Wikipedia

   en.wikipedia.org/wiki/Management_of_heart_failure

   Sleep apnea is an under-recognized risk factor for heart failure. Uncontrolled sleep apnea may increase the risk of heart failure by up to 140%. [4] Weight reduction – through physical activity and dietary modification, as obesity is a risk factor for heart failure and left ventricular hypertrophy. Effective weight management has been shown ...

7. Canagliflozin - Wikipedia

   en.wikipedia.org/wiki/Canagliflozin

   Canagliflozin is indicated to be used with diet and exercise to lower blood sugar in adults with type 2 diabetes; to reduce the risk of major heart-related events such as heart attack, stroke, or death in people with type 2 diabetes who have known heart disease; and to reduce the risk of end-stage kidney disease, worsening of kidney function, heart-related death, and being hospitalized for ...